NIH Biosafety in Grant Applications: IBC Approval, Select Agents, and the 2026 Draft Policy

Why Biosafety Belongs in Your Grant Application

NIH requires all grantee institutions to comply with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules — commonly called the rDNA Guidelines — as a condition of receiving NIH support. That requirement doesn't sit passively in the background. It means your Institutional Biosafety Committee (IBC) has a direct line into your award process, and if that line isn't in order, your Notice of Award can be delayed or withheld even after a favorable review.

Most applicants understand that IRB approval is required for human subjects research. Fewer appreciate that IBC approval runs on a parallel track for biohazard-relevant work, and that the two processes have different timing requirements. IRB approval is typically not required before submission for most research; IBC approval is similarly not required at submission, but you must have it before NIH can issue an award. Plan for that gap now, not when you get a JIT request.

The NIH rDNA Guidelines: What They Cover and Who Must Comply

The NIH rDNA Guidelines apply to all research involving recombinant or synthetic nucleic acid molecules conducted at or sponsored by institutions that receive NIH support. In practice, that scope is broad. Gene-editing experiments using CRISPR-Cas9, work with recombinant viral vectors (lentivirus, AAV, adenovirus), studies using bacterial or mammalian expression systems carrying foreign genes, and research with organisms or viruses constructed to contain recombinant sequences all fall under these Guidelines. If your proposed work touches any of those categories, your institution's IBC must review and register the relevant protocols.

The IBC's role is to assess the biosafety level (BSL) appropriate for your work — BSL-1 through BSL-4, representing increasing levels of containment — and to verify that your institutional facilities match that classification. For most academic researchers, the relevant level is BSL-2, which covers a wide range of molecular biology and virology work. The IBC's written approval of your protocol is what NIH's grants management staff will look for before issuing your award. The message for grant writers: describe your containment level explicitly in the Facilities and Resources section, and don't assume reviewers will infer it from your methods.

Select Agents: Extra Requirements and Longer Lead Times

A subset of pathogens and toxins — designated as Select Agents and Toxins under federal law — require registration with the CDC Select Agent Program or USDA APHIS before research can begin at your institution. Unlike standard IBC approval, which your institution can grant relatively quickly, Select Agent registration involves a federal inspection process that can take months. If your proposed NIH work even plausibly involves a Select Agent, contact your institutional biosafety officer well before you finalize your Specific Aims, because the registration timeline could affect your project start date in ways that reviewers will notice if your approach reads as if the work could start in month one.

For the NIH application itself, you'll need to describe your institution's Select Agent compliance status in the Facilities section and acknowledge the registration requirement in your research plan. NIH grants management will not issue an award for Select Agent work without written certification that your facility holds current federal registration. Grants involving both Select Agents and human subjects or animal protocols add a third layer of timing coordination: don't let any one of those approvals become the bottleneck that delays the other two.

Dual-Use Research of Concern (DURC): How NIH Reviews High-Risk Projects

The U.S. Government Policy for Institutional Oversight of Life Sciences Dual-Use Research of Concern defines specific categories of research — particularly involving pathogens that could pose pandemic or bioweapon risks — that must undergo additional institutional and sometimes federal review before NIH can fund them. If your proposed work involves research to enhance the transmissibility, pathogenicity, or immune evasion of certain agents, or if you're working with agents that fall under DURC policy categories, your institution's Institutional Review Entity for DURC needs to evaluate your project. This is a separate review from IBC approval, and it can add weeks to months to your pre-award process.

NIH program staff also screen incoming applications for DURC characteristics during the review process. If your application is flagged, that review can affect study section assignment and introduce a supplemental review layer not visible to standard applicants. The practical advice: if there's any chance your proposed work touches DURC criteria, loop in your institutional biosafety and research compliance offices before submission, not after. A proactive conversation with your NIH Program Officer about DURC applicability — before you finalize your research plan — is also a reasonable step.

The August 2026 Draft Biosafety Policy: A Broader Framework Is Coming

On August 19, 2026, NIH released a Draft Biosafety Policy for Research Involving Biohazards for public comment. The draft is intended to replace the current rDNA Guidelines with a broader framework that covers research involving biological hazards more comprehensively — not just recombinant and synthetic nucleic acid molecules, but a wider range of biohazardous materials and activities. The comment period was still open as of this writing; check grants.nih.gov for the current deadline and the draft text if your work involves biohazard-relevant research.

What the transition means for applicants: the current rDNA Guidelines remain in effect until a final policy is issued, and applications submitted under the current framework will be reviewed under the rules in effect at submission. That said, the direction of travel is toward broader IBC oversight, not narrower. If your proposed work sits in a gray zone under the current Guidelines — some synthetic biology projects and certain cell-engineering approaches can be ambiguous — the draft's broader scope is a signal that your institution's biosafety office should be involved now. Getting ahead of a policy transition during the grant development phase is easier than navigating it during JIT.

How to Describe Biosafety in Your Research Strategy

The right home for biosafety language in your NIH application is the Facilities and Other Resources section. That's where reviewers — and grants management staff — look for confirmation that your institution is equipped to do the proposed work safely. For BSL-2 and above, include an explicit statement: name the BSL level, confirm that your institution maintains an active IBC, and note whether protocol approval is in place or in progress. A sentence like "All recombinant viral vector work will be conducted at BSL-2 in our certified containment suite, under an active IBC protocol approved through [institution name]" is usually sufficient. Don't make reviewers hunt for this.

For Select Agent work or DURC-relevant research, a brief mention in the Approach section — in addition to the Facilities section — is appropriate when the containment requirements directly affect how you propose to conduct specific experiments. Reviewers score feasibility in part on whether your institutional environment can support the proposed work. If the answer requires regulatory compliance steps, show that you've anticipated those steps and built them into your timeline and budget. Ignoring biosafety compliance in the application because you plan to address it later is one of the quieter ways to give reviewers a feasibility concern they didn't arrive with.

Frequently Asked Questions